"This is why you do a phase II," H.C. Wainwright & Co. analyst Corey Davis headlined his note assessing top-line data posted by Cara Therapeutics Inc. on its phase IIb trial of the oral formulation of its peripherally selective kappa opioid agonist, CR-845, in patients with osteoarthritis (OA) of the knee or hip.